会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明申请
    • POLYALKYLENEOXYDIAMINE POLYAMIDES USEFUL FOR FORMULATING INKS FOR PHASE-CHANGE JET PRINTING
    • 聚丙烯酰胺胺聚氨酯用于配制油墨用于相变喷嘴印刷
    • WO01087847A2
    • 2001-11-22
    • PCT/US2001/014980
    • 2001-05-08
    • C08G69/40C09D11/00C07D233/00
    • C09D11/34C08G69/40
    • A compound of formula (1): R -C(=O)-(NH-R -NHC(=O)-R -C(=O))n-NH-R -NHC(=O)-R (1) wherein, in at least one occurrence, R is an alkyl group having at least seventeen carbons; R includes a polyalkyleneoxide; R includes a C6 carbocyclic group; and n is an integer of at least 1. A process for preparing a compound of the formula (1) comprising combining reactants comprising: (a) a monoacid compound of the formula R -COOH, or a reactive equivalent thereof; (b) a diamine compound of the formula H2N-R -NH2, or a reactive equivalent thereof; and (c) a diacid compound of the formula HOOC-R -COOH, or a reactive equivalent thereof; and heating reactants (a), (b) and (c) at a sufficient temperature, and for a sufficient time, to provide a reaction product that comprises a compound of formula (1). A process of printing, the process including melting a compound of formula (1) and depositing compound of formula (1) onto a substrate.
    • 式(1)的化合物:R 1 -C(= O) - (NH-R 2 -NHC(= O)-R 3 -C(= O))n -NH-R 2> -NHC(= O)-R 1(1)其中,在至少一次出现中,R 1是具有至少17个碳原子的烷基; R 2包括聚环氧烷; R 3包括C6碳环基团; 并且n是至少为1的整数。1.一种制备式(1)化合物的方法,包括将反应物组合,包括:(a)式R 1 -COOH的一元酸化合物或其反应当量; (b)式H 2 N-R 2 -NH 2的二胺化合物或其反应性等同物; 和(c)式HOOC-R 3 -COOH的二酸化合物或其反应性等同物; 和加热反应物(a),(b)和(c)在足够的温度下反应足够的时间以提供包含式(1)化合物的反应产物。 一种印刷方法,该方法包括将式(1)化合物熔融并将式(1)化合物沉积在基材上。
    • 23. 发明申请
    • SUBSTITUTED 1-(4-AMINOPHENYL)IMIDAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
    • 取代的1-(4-氨基苯基)咪唑烷及其作为抗炎剂的用途
    • WO0170703A2
    • 2001-09-27
    • PCT/US0109262
    • 2001-03-22
    • BOEHRINGER INGELHEIM PHARMA
    • BETAGERI RAJASHEKHAR
    • A61P37/06C07D233/54C07D233/00
    • C07D233/64
    • A compound of Formula (Ia) or (Ib) wherein R1 and R2, which may be the same or different, are CF3; halogen; CN; branched or unbranched C1-8 alkyl; branched or unbranched C1-8 alkenyl; C3-8 cycloalkyl optionally substituted with OH, CN, or methoxy; C1-8 alkoxy; C1-4 alkyloxyalkyl; C1-8 alkylthio; C1-4 alkylthioalkyl; C1-8 dialkylamino; C1-4 dialkylaminoalkyl; CO2R4 where R4 is C1-4 alkyl or C1-4 alkenyl optionally substituted with carbocyclyl or heterocyclyl; aryl or heterocyclyl connected to the imidazole in any position that makes a stable bond which aryl or heterocyclyl is optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4; L is -NHC(O)-; -NHC(O)O-; -NHC(O)C(O)-; -NHC(S)-; -NH-; -NHC(O)NH-; -NHC(S)NH-; -NHCH2-; -NHCH(R5)- where R5 is H, CN, C1-6 alkyl, C1-6 alkyloxyoalkyl C1-6 alkythioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkysulfonylalkyl, C3-6 cycloalkyl, heterocyclyl, or aryl optionally substituted with a halogen, C1-4 alkyl, CN, Me2N, CO2Me, or OMe; or L is -NHC(R5)-lower alkyl; R3 is C1-8 alkyl; C1-8 alkyloxy; C1-8 alkylthio; C1-8 alkylamino; C1-4 alkoxyalkyl; C1-4 alkylthioalkyl; C1-4 alkylaminoalkyl; C1-4 dialkylalkylaminoalkyl; carbocyclyl or heterocyclyl, which carbocyclyl or heterocyclyl is optionally substituted with one or more of the following: halogen, -CN, -NO2, -SO2NH2, or R6 (where R6 is phenyl, heterocyclyl, C3-6 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkylsulfonylalkyl, or C2-6 alkynyl) and R6 is optionally substituted with halogen, -OH, alkyloxy, -CN, -COO-lower alkyl, -CONH-lower alkyl, -CON (lower alkyl)2, dialkylamino, phenyl, or heterocyclyl; or R3 is -CO2R6; -N(R6)2; -NH(R6); -C(O)R6; -OR6; S(O)nR6 where n is O, 1, or 2; -SO2NHR6; or -SO2N(R6)2; or a pharmaceutically acceptable derivative thereof.
    • 式(Ia)或(Ib)的化合物,其中R 1和R 2可以相同或不同,为CF 3; 卤素; CN; 支链或非支链C1-8烷基; 支链或非支链C 1-8烯基; 任选被OH,CN或甲氧基取代的C 3-8环烷基; C 1-8烷氧基 C 1-4烷氧基烷基; C 1-8烷硫基; C 1-4烷硫基烷基; C 1-8二烷基氨基; C 1-4二烷基氨基烷基 CO 2 R 4,其中R 4是C 1-4烷基或任选被碳环基或杂环基取代的C 1-4链烯基; 芳基或杂环基与任何能够形成稳定键的位置,芳基或杂环基任选被卤素,C 1-4烷基,C 1-4烯基,CN,Me 2 N,CO 2 Me,OMe,芳基,杂环基或R 4取代; L是-NHC(O) - ; -NHC(O)O-; -NHC(O)C(O) - ; -NHC(S) - ; -NH-; -NHC(O)NH-; -NHC(S)NH-; -NHCH 2; -NHCH(R5) - 其中R5是H,CN,C1-6烷基,C1-6烷氧基烷基C1-6链烷基,C1-6烷基亚磺酰基烷基,C1-6烷基磺酰基烷基,C3-6环烷基,杂环基或任选被 卤素,C 1-4烷基,CN,Me 2 N,CO 2 Me或OMe; 或L是-NHC(R5) - 低级烷基; R3是C1-8烷基; C 1-8烷氧基; C 1-8烷硫基; C 1-8烷基氨基; C 1-4烷氧基烷基; C 1-4烷硫基烷基; C 1-4烷基氨基烷基 C 1-4烷基烷基氨基烷基 碳环基或杂环基,其碳环基或杂环基任选被一个或多个下列基团取代:卤素,-CN,-NO 2,-SO 2 NH 2或R 6(其中R 6是苯基,杂环基,C 3-6环烷基,C 1-6烷基, C 2-6烷氧基烷基,C 1-6烷硫基烷基,C 1-6烷基亚磺酰基烷基,C 1-6烷基磺酰基烷基或C 2-6炔基),R 6任选被卤素,-OH,烷氧基,-CN,-COO- 低级烷基,-CONH-低级烷基,-CON(低级烷基)2,二烷基氨基,苯基或杂环基; 或R 3为-CO 2 R 6; -N(R 6)2; -NH(R 6); -C(O)R 6; -OR6; S(O)n R 6,其中n为O,1或2; -SO2NHR6; 或-SO 2 N(R 6)2; 或其药学上可接受的衍生物。